Clinical trial

Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of…

NCT00232297 · Sanofi, Industry · Completed

Key facts

NCT number NCT00232297
Title Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS
Official title Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744C 100 OR 300 mg for the Prevention of Ventricular Arrhythmia-Triggered ICD Interventions
Acronym ICARIOS
Lead sponsor Sanofi, Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Arrhythmia, Tachycardia, Ventricular, Ventricular Fibrillation
Intervention type Drug
Interventions SSR149744C
Enrollment 153
Start date Jun 1, 2005
Primary completion Feb 1, 2007
Completion Feb 1, 2007
First posted Oct 4, 2005
Last update posted May 8, 2012
Countries Belgium, Canada, Czechia, Germany, Italy, Netherlands, Switzerland, United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies